The FDA urges manufacturers to revise labeling of transmucosal buprenorphine products to ease access to higher doses because ...
Naloxone treats a condition that can be identified or self-diagnosed without a medical professional’s guidance, it has a very low misuse potential, and label instructions are understandable to a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback